FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4387563818> ?p ?o ?g. }

• W4387563818 abstract "Psoriasis, an incurable chronic inflammatory disease, affects over 6 million people in China. Ixekizumab, a monoclonal antibody against interleukin-17A, has demonstrated efficacy and safety for the treatment of moderate-to-severe plaque psoriasis, although limited data are available regarding its use in routine clinical practice in China. We investigated the real-world application of ixekizumab in China.Adults (≥ 18 years) with moderate-to-severe plaque psoriasis prescribed ixekizumab in routine clinical practice were enrolled in this prospective, observational, single-arm, multicenter, post-marketing surveillance study. The primary endpoint was the safety of ixekizumab at week 12. The effectiveness of ixekizumab, based on the Psoriasis Area and Severity Index (PASI) and Dermatology Life Quality Index (DLQI), was assessed as a secondary endpoint.In total, 666 patients were enrolled; 663 were included in the safety analysis, and 612 in the effectiveness analysis. At least one adverse event (AE) was reported by 42.7% (283/663) of patients, most of which were mild (242/283, 85.5%), and 32.7% (217/663) of patients reported AEs related to study treatment. The most frequently reported AEs were injection site reactions. AEs led to discontinuation in five patients (0.8%). Only three patients had a serious AE. Mean ± standard deviation (SD) change from baseline in PASI score was reduction in 10.79 ± 9.55 at week 2 and 16.80 ± 12.15 at week 12. At week 2, 63.7% of patients achieved PASI 50. At week 12, 93.2%, 77.4%, and 45.1% of patients achieved PASI 75, PASI 90, and PASI 100, respectively. Mean ± SD change from baseline in DLQI was reduction in 5.91 ± 6.27 at week 2 and 9.76 ± 7.16 at week 12. DLQI 0/1 was achieved by 19.8% and 59.9% of patients at week 2 and 12, respectively.Ixekizumab was well tolerated and effective in real-world clinical practice in Chinese adults with moderate-to-severe plaque psoriasis." @default.
• W4387563818 created "2023-10-13" @default.
• W4387563818 creator A5002808615 @default.
• W4387563818 creator A5005196775 @default.
• W4387563818 creator A5022006244 @default.
• W4387563818 creator A5024215964 @default.
• W4387563818 creator A5040590821 @default.
• W4387563818 creator A5043153854 @default.
• W4387563818 creator A5049887641 @default.
• W4387563818 creator A5055054595 @default.
• W4387563818 creator A5072924983 @default.
• W4387563818 creator A5093048693 @default.
• W4387563818 creator A5093048694 @default.
• W4387563818 creator A5093048695 @default.
• W4387563818 creator A5093048696 @default.
• W4387563818 creator A5093048697 @default.
• W4387563818 date "2023-10-12" @default.
• W4387563818 modified "2023-10-13" @default.
• W4387563818 title "Safety and Efficacy of Ixekizumab in Chinese Adults with Moderate-to-Severe Plaque Psoriasis: A Prospective, Multicenter, Observational Study" @default.
• W4387563818 cites W1727561536 @default.
• W4387563818 cites W1982598880 @default.
• W4387563818 cites W2030298480 @default.
• W4387563818 cites W2112626870 @default.
• W4387563818 cites W2171889601 @default.
• W4387563818 cites W2339525054 @default.
• W4387563818 cites W2418506270 @default.
• W4387563818 cites W2561759163 @default.
• W4387563818 cites W2625791318 @default.
• W4387563818 cites W2972819009 @default.
• W4387563818 cites W2988907058 @default.
• W4387563818 cites W3012894524 @default.
• W4387563818 cites W3089931729 @default.
• W4387563818 cites W3126106680 @default.
• W4387563818 cites W4200104697 @default.
• W4387563818 cites W4205377423 @default.
• W4387563818 cites W4206807641 @default.
• W4387563818 cites W4283271473 @default.
• W4387563818 doi "https://doi.org/10.1007/s12325-023-02672-1" @default.
• W4387563818 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37824031" @default.
• W4387563818 hasPublicationYear "2023" @default.
• W4387563818 type Work @default.
• W4387563818 citedByCount "0" @default.
• W4387563818 crossrefType "journal-article" @default.
• W4387563818 hasAuthorship W4387563818A5002808615 @default.
• W4387563818 hasAuthorship W4387563818A5005196775 @default.
• W4387563818 hasAuthorship W4387563818A5022006244 @default.
• W4387563818 hasAuthorship W4387563818A5024215964 @default.
• W4387563818 hasAuthorship W4387563818A5040590821 @default.
• W4387563818 hasAuthorship W4387563818A5043153854 @default.
• W4387563818 hasAuthorship W4387563818A5049887641 @default.
• W4387563818 hasAuthorship W4387563818A5055054595 @default.
• W4387563818 hasAuthorship W4387563818A5072924983 @default.
• W4387563818 hasAuthorship W4387563818A5093048693 @default.
• W4387563818 hasAuthorship W4387563818A5093048694 @default.
• W4387563818 hasAuthorship W4387563818A5093048695 @default.
• W4387563818 hasAuthorship W4387563818A5093048696 @default.
• W4387563818 hasAuthorship W4387563818A5093048697 @default.
• W4387563818 hasBestOaLocation W43875638181 @default.
• W4387563818 hasConcept C126322002 @default.
• W4387563818 hasConcept C16005928 @default.
• W4387563818 hasConcept C197934379 @default.
• W4387563818 hasConcept C203092338 @default.
• W4387563818 hasConcept C23131810 @default.
• W4387563818 hasConcept C2776173921 @default.
• W4387563818 hasConcept C2776260265 @default.
• W4387563818 hasConcept C2777011040 @default.
• W4387563818 hasConcept C2778715236 @default.
• W4387563818 hasConcept C2779745271 @default.
• W4387563818 hasConcept C2779786854 @default.
• W4387563818 hasConcept C2780564577 @default.
• W4387563818 hasConcept C3020604521 @default.
• W4387563818 hasConcept C535046627 @default.
• W4387563818 hasConcept C71924100 @default.
• W4387563818 hasConceptScore W4387563818C126322002 @default.
• W4387563818 hasConceptScore W4387563818C16005928 @default.
• W4387563818 hasConceptScore W4387563818C197934379 @default.
• W4387563818 hasConceptScore W4387563818C203092338 @default.
• W4387563818 hasConceptScore W4387563818C23131810 @default.
• W4387563818 hasConceptScore W4387563818C2776173921 @default.
• W4387563818 hasConceptScore W4387563818C2776260265 @default.
• W4387563818 hasConceptScore W4387563818C2777011040 @default.
• W4387563818 hasConceptScore W4387563818C2778715236 @default.
• W4387563818 hasConceptScore W4387563818C2779745271 @default.
• W4387563818 hasConceptScore W4387563818C2779786854 @default.
• W4387563818 hasConceptScore W4387563818C2780564577 @default.
• W4387563818 hasConceptScore W4387563818C3020604521 @default.
• W4387563818 hasConceptScore W4387563818C535046627 @default.
• W4387563818 hasConceptScore W4387563818C71924100 @default.
• W4387563818 hasFunder F4320321001 @default.
• W4387563818 hasFunder F4320335796 @default.
• W4387563818 hasLocation W43875638181 @default.
• W4387563818 hasLocation W43875638182 @default.
• W4387563818 hasOpenAccess W4387563818 @default.
• W4387563818 hasPrimaryLocation W43875638181 @default.
• W4387563818 hasRelatedWork W2333727839 @default.
• W4387563818 hasRelatedWork W2565883611 @default.
• W4387563818 hasRelatedWork W2587065397 @default.
• W4387563818 hasRelatedWork W2602145888 @default.
• W4387563818 hasRelatedWork W3015278864 @default.
• W4387563818 hasRelatedWork W3084613618 @default.

• next